Product Description
Viscosupplementation is a medical procedure during which lubricating fluid is injected into a joint. Also called hyaluronic acid injections or hyaluronan injections, viscosupplementation is most commonly used to treat symptoms of symptoms of knee osteoarthritis.
The Hyaluronic Acid Viscosupplementation market revenue was xx Million USD in 2019, grew to xx Million USD in 2023, and will reach xx Million USD in 2031, with a CAGR of xx during 2024-2031.
Considering the influence of COVID-19 on the global Hyaluronic Acid Viscosupplementation market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Japan, the report put emphasis on analysis of market under COVID-19 and corresponding response policy in different regions.
This report also analyzes the strategies for different companies to deal with the impact of COVID-19 in detail to seek a path to recovery.
Under COVID-19 Outbreak, how the Hyaluronic Acid Viscosupplementation Industry will develop is also analyzed in detail in Chapter 1.8 of this report.
Major Players in Hyaluronic Acid Viscosupplementation market are:
Croma-Pharma
Meda Pharma
Anika Therapeutics Inc.
Zimmer, Inc.
Laboratoire Genevrier
Swiss biomed Orthopaedics AG
Tedec Meiji
Carbylan Therapeutics
TRB Chemedica
Supartz
Synvisc - One
Most important types of Hyaluronic Acid Viscosupplementation products covered in this report are:
Single Injection
Multiple Injections
Most widely used downstream fields of Hyaluronic Acid Viscosupplementation market covered in this report are:
Knee Osteoarthritis
Hip Osteoarthritis
Ankle Osteoarthritis
Shoulder Osteoarthritis
Major Regions or countries covered in this report:
North America
Europe
China
Japan
Middle East and Africa
South America
India
South Korea
Southeast Asia
Others
In Chapter 3.4, the report provides analysis of the reasons behind price fluctuations.
In chapters 5, 6, and 7, the impact of COVID-19 on the different regions in both production and consumption end and SWOT analysis are pointed out.
In Chapters 8, the report presents company's recent development and strategies to deal with the impact of COVID-19.